Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02584478
Title	Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
Acronym	AL3818
Recruitment	Active, not recruiting
Gender	female
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	Advenchen Laboratories, LLC
Indications	fallopian tube cancer cervical cancer uterine cancer endometrial cancer cervical adenosquamous carcinoma endometrioid ovary carcinoma cervical squamous cell carcinoma ovary adenocarcinoma peritoneum cancer ovarian cancer ovarian clear cell adenocarcinoma cervical adenocarcinoma ovarian seromucinous carcinoma ovary serous adenocarcinoma
Therapies	Anlotinib + Carboplatin + Paclitaxel
Age Groups:	adult \| senior
Covered Countries	USA \| ITA \| GBR \| ESP